関連する実験動画
Updated: Jul 6, 2026
07:46
Assessing Endothelial Vasodilator Function with the Endo-PAT 2000
Published on: October 15, 2010
L-アルギニンの輸送と内皮機能の障害は,高血圧および遺伝的傾向のある正常血圧の被験者における障害である
Markus P Schlaich1, Melinda M Parnell, Belinda A Ahlers
1Wynn Department of Metabolic Cardiology, Baker Heart Research Institute, Melbourne, Victoria, Australia.
Circulation
|December 1, 2004
まとめ
L-アルギニン輸送の障害は,本質的な高血圧に関連しており,高血圧のリスクを予測します. L-アルギニンを補充すると,高血圧と家族歴のある人の血管拡張が改善されました.
科学分野:
- 心血管生理学 心血管の生理学
- 高血圧病理生理学 高血圧病理生理学
- 内皮機能の機能について
背景:
- エッセンシャル高血圧は,内皮に依存したNO媒介の血管拡張の障害によって特徴付けられます.
- この内皮機能不全は,高血圧に先行する可能性があります.
- この過程におけるL-アルギニン輸送の役割が調査されました.
研究 の 目的:
- 主要高血圧におけるL-アルギニン輸送と内皮機能不全の関係を調査する.
- L-アルギニンの摂取量を高血圧患者および高血圧の家族歴のある,またはない健康な個体で評価する.
- L-アルギニンのサプリメントが,リスクのある個人の内皮機能を改善できるかどうかを判断する.
主な方法:
- 放射性トレーサー運動 ([3H]L-アルギニン) を利用して,前腕と外周血液単核細胞のアルギニン吸収量を測定した.
- アセチルコリンとナトリウムニトロプロシドに対する前腕の血流反応を評価した.
- 測定されたL-アルギニン輸送 in vivoおよびin vitro,CAT-1発現とプラズマADMA濃度とともに.
主要な成果:
- L-アルギニン輸送は,エッセンシャル高血圧と陽性家族歴のグループで有意に減少しました.
- グループ間では,CAT-1 mRNA/タンパク質またはプラズマL-アルギニン/ADMAの差異は認められなかった.
- 静脈内投与L-アルギニンは,エッセンシャル高血圧および家族歴が陽性であったグループでのみアセチルコリン反応を改善した.
結論:
- 高血圧のリスクが高い正常血圧の個人は,高血圧の患者と同様に,L-アルギニン輸送の障害を示します.
- L-アルギニン輸送におけるこの欠陥は,欠陥のあるL-アルギニン/NO経路と本質的な高血圧の発達を関連付けている可能性があります.
- トランスポートの欠陥は,CAT-1発現の変化やADMA濃度の上昇によって説明されません.
関連する概念動画
01:28Nitric Oxide Signaling Pathway
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
01:18Hypertension and Regulation of Blood Pressure
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:29Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...